Pharmaceuticals & Biotech/Lifesciences

FNArena Windows (Sectors)

Introduction to FNArena Windows

FNArena Windows offers subscribers the option to investigate ASX-listed stocks against their peers. FNArena developed its own sector methodology which in our view overcomes many flaws and disadvantages connected with GICS sectors. Our system starts with three broad sector labels: COMMODITIES, FINANCIAL SERVICES and INDUSTRIALS. From here onwards subscribers can explore further through gradually narrowing branches. This is not investment advice, but simply another window on the Australian Stock Exchange to provide better insight and to assist FNArena subscribers while conducting their own market analysis.

Latest Stories

As per the New Criterion’s Tim Boreham, Invion is an old company on a new mission

May 13 2024

Race Oncology tells a story all too familiar among developing Aussie biotechs, Tim Boreham reports

Apr 09 2024


ASX CODE COMPANY NAME LAST PRICE 52WK HIGH 52WK LOW P/E CONSENSUS TARGET
ARX AROA BIOSURGERY LIMITED $0.52 $1.01 $0.48 70.3

$0.975

AVH AVITA MEDICAL INC $2.52 $6.27 $2.38

$5.10

CSL CSL LIMITED $280.64 $312.99 $228.65 30.0

$316.733

CUV CLINUVEL PHARMACEUTICALS LIMITED $15.62 $21.45 $12.96 22.5

$18.75

GSS GENETIC SIGNATURES LIMITED $0.69 $0.78 $0.38

$0.75

IMM IMMUTEP LIMITED $0.45 $xx.xx $xx.xx xx.x xx.xx
IMU IMMUTEP LIMITED $0.07 $xx.xx $xx.xx xx.x xx.xx
MAP MICROBA LIFE SCIENCES LIMITED $0.20 $xx.xx $xx.xx xx.x xx.xx
MSB MESOBLAST LIMITED $1.16 $xx.xx $xx.xx xx.x xx.xx
NEU NEUREN PHARMACEUTICALS LIMITED $23.97 $xx.xx $xx.xx xx.x xx.xx
PAR PARADIGM BIOPHARMACEUTICALS LIMITED $0.27 $xx.xx $xx.xx xx.x xx.xx
PBP PROBIOTEC LIMITED $2.96 $xx.xx $xx.xx xx.x xx.xx
PER PERCHERON THERAPEUTICS LIMITED $0.07 $xx.xx $xx.xx xx.x xx.xx
PNV POLYNOVO LIMITED $2.11 $xx.xx $xx.xx xx.x xx.xx
PYC POLYNOVO LIMITED $0.12 $xx.xx $xx.xx xx.x xx.xx
TLX TELIX PHARMACEUTICALS LIMITED $15.89 $xx.xx $xx.xx xx.x xx.xx
Previous Stories
The Power Of New Weight-Loss Drugs

Apr 03 2024

GLP-1s offer far more across the healthcare sector than just weight-loss, with far-reaching societal implications, explains T. Rowe Price’s Nabil Hanano


Dr Boreham’s Crucible: Neuren Pharmaceuticals

Mar 11 2024

Tim Boreham reports Neuren Pharmaceuticals has suffered from accusations from an activist shorter which others have debunked


Spotlight On ASX-Listed Cannabis Companies

Jan 31 2024

Some cannabis gems are sprouting in the ASX weed patch, but they are hard to find in the haze of hype, Tim Boreham, Editor, The New Criterion reports


Transformational Trial Results For Neuren Pharmaceuticals

Dec 20 2023

Brokers raise valuations for Neuren Pharmaceuticals following positive Phase 2 clinical trial results


Dr Boreham’s Crucible: Imugene

Dec 11 2023

Tim Boreham highlights the prospects for cancer treatment biotech Imugene


Dr Boreham’s Crucible: PYC Therapeutics

Nov 22 2023

Tim Boreham highlights how PYC Therapeutics’ gene therapy can address a plethora of genetic afflictions


Dr Boreham’s Crucible: Paradigm Biopharmaceuticals

Nov 06 2023

Tim Boreham highlights the success of Paradigm Biopharmaceuticals’ joint pain drug ahead of a capital raising


Dr Boreham’s Crucible: Argenica Therapeutics

Sep 28 2023

Argenica Therapeutics is aiming for a substantial slice of the stroke market, expected to be worth some US$180bn a year by 2030


Dr Boreham’s Crucible: Cleo Diagnostics

Aug 30 2023

Tim Boreham shines a light on freshly listed Cleo Diagnostics, in search of an effective diagnostic tool for ovarian cancer


Breaking Boundaries: Medical Psychedelics

Aug 21 2023

Australia is the first country in the world to legalise the use of psychedelic drugs for mental illness